Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | CLK2 | P49760 | 2/20 | 0.46 |
| ▸ | GSK3A | P49840 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | PRKX | P51817 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.46 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.46 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530533 | 0.78 | PARP1 (0.54) | PARP1GPR84FEN1 | |
| SCHEMBL8621146 | 0.78 | PARP1 (0.54) | PARP1GPR84FEN1 | |
| SCHEMBL11343387 | 0.75 | PARP1 (0.37) | PARP1DYRK1AAURKADAPK3PRKD3 | |
| SCHEMBL8813028 | 0.74 | ABL1 (0.49) | PARP1ABL1GAAKDM4EALDH1A1 | |
| SCHEMBL196738 | 0.72 | PARP1 (0.56) | PARP1DYRK1AAURKADAPK3PRKD3 | |
| SCHEMBL10881189 | 0.70 | GAA (0.49) | PARP1DYRK1AGPR84GAAERCC5 | |
| SCHEMBL4708864 | 0.70 | PARP1 (1.00) | PARP1DYRK1AAURKADAPK3PRKD3 | |
| SCHEMBL19810765 | 0.69 | CYP1A2 (0.51) | PARP1DYRK1AGPR84NR4A2ERCC5 | |
| Quinazolinone SCHEMBL10418 | 0.68 | PARP1 (0.48) | PARP1DYRK1AAURKADAPK3PRKD3 | |
| SCHEMBL19153000 | 0.68 | PDE3B (0.44) | PARP1PIM1RPS6KA3CDK5ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309596-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-02-06 | — | — | EP | disclosed |
| US-6844435-B2 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20030207902-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1309596-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6489328-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; ANTIPROLIFERATIVE AGENTS; ANTICANCER AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020119975-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002014319-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| US-5849861-A | Polyquinazolines and methods for their preparation | HITACHI CHEMICAL CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| US-5686560-A | TREATING A MONOMER WITH A BASE IN A DIPOLAR SOLVENT | HITACHI CHEMICAL CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
| US-4182630-A | COLOR PHOTOGRAPHY | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119975-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, JAK1, LCK | PARP1 1095/4885DYRK1A 1138/4885AURKA 957/4885 |
| US-20030207902-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, JAK1, LCK | PARP1 1095/4885DYRK1A 1138/4885AURKA 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.